Zhong et al. reported that HoxB13 firstly combined with AR-V7 through direct physical interaction, and cooperated with AR-V7 to up regulate target oncogenes, which is a key upstream regulator of the AR-V7 driven transcriptome, indicating that HoxB13 can be used as a therapeutic target for AR-V7 driven prostate tumors [147]. This evidence concerns the gene HOXB13 and prostate neoplasm.